- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | Dogwood Therapeutics appoints Iain Dukes to lead advisory board | 1 | Investing.com | ||
| 30.06. | Iain Dukes leitet neuen wissenschaftlichen Beirat von Dogwood Therapeutics | - | Investing.com Deutsch | ||
| 30.06. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board | 158 | GlobeNewswire (Europe) | ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines... ► Artikel lesen | |
| 17.06. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | 300 | GlobeNewswire (Europe) | New study to assess Halneuron pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Dogwood Therapeutics GAAP EPS of -$0.15 | 1 | Seeking Alpha | ||
| 14.05. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces First Quarter 2026 Financial Results | 781 | GlobeNewswire (Europe) | - Halneuron- Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy... ► Artikel lesen | |
| 15.04. | Dogwood Therapeutics Announces FDA Acceptance Of IND Application For SP16 | 1 | RTTNews | ||
| 15.04. | Dogwood Therapeutics receives FDA clearance for SP16 pain trial | 2 | Investing.com | ||
| 15.04. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy | 214 | GlobeNewswire (Europe) | Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected... ► Artikel lesen | |
| 26.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Dogwood Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | Virios Therapeutics GAAP EPS of -$0.26 | 1 | Seeking Alpha | ||
| 18.03. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | 456 | GlobeNewswire (Europe) | ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy... ► Artikel lesen | |
| 12.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development | 199 | GlobeNewswire (Europe) | Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics... ► Artikel lesen | |
| 22.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | 414 | GlobeNewswire (Europe) | - Halneuron- treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below... ► Artikel lesen | |
| 02.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Files New Synthetic Halneuron Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | 322 | ACCESS Newswire | - New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron-- New Synthetic Process to be Used for Phase 3 Development Provides... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,31 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| EVOTEC | 3,440 | -0,64 % | Evotec gibt Gewinnhoffnung für 2026 auf - Niedrigere Erlöse als erwartet | HAMBURG (dpa-AFX) - Der Wirkstoff-Entwickler Evotec senkt wegen nun erwarteter Umsatzverschiebungen und geringerer Erlöserwartungen seine Jahresziele deutlich. 2026 sei mit einem Umsatz von 570 bis... ► Artikel lesen | |
| VALNEVA | 2,146 | -0,51 % | BRANDMELDUNG bei Valneva: Warum Insider bereits massiv kaufen - So reagieren erfahrene Anleger jetzt | ||
| AMGEN | 318,50 | -0,52 % | After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset | ||
| NOVAVAX | 7,130 | -0,83 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 178,32 | -0,96 % | Biogen vor Alzheimer-Durchbruch? | Die Biotechnologie hat in den zurückliegenden Jahren für jede Menge Durchbrüche bei der Behandlung von teils schwerwiegenden Krankheiten gesorgt. Doch es gab auch Rückschläge. Vor allem die Alzheimer-Forschung... ► Artikel lesen | |
| BIOFRONTERA | 2,450 | +3,38 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,217 | +0,93 % | Bayer und Novo Nordisk feiern Comeback! BioNxt Solutions Aktie als Nächstes? | Mit seiner GLP-1-Therapie in Tablettenform hat Novo Nordisk an der Börse wieder in die Erfolgsspur zurückgefunden. Seit April ist die Aktie des dänischen Pharmakonzerns um fast 50 % auf rund 43 EUR... ► Artikel lesen | |
| CLINUVEL | 6,190 | +1,54 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| VIKING THERAPEUTICS | 32,250 | -0,62 % | Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note | ||
| INTELLIA THERAPEUTICS | 9,990 | +0,40 % | Wolfe Research stuft Intellia Aktie wegen Bewertungsbedenken herab | ||
| TEMPUS AI | 46,030 | +0,37 % | Biovica International: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI | UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announces that it has, by... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,256 | +1,99 % | Defence Therapeutics Inc.: Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform | Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,580 | -0,77 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,044 | -0,89 % | BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer | PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.In... ► Artikel lesen |
DOGWOOD THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,72 % bei einem Aktienkurs von 1,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DOGWOOD THERAPEUTICS INC finden Sie auf Wallstreet Online.